Sulfamethoxazole is an antibiotic. It is used for bacterial infections such as urinary tract infections, bronchitis, and prostatitis and is effective against both gram negative and positive bacteria such as Escherichia coli and Listeria monocytogenes. Chemically it is a sulfonamide that inhibits dihydropteroate synthase, blocking para-aminobenzoic acid incorporation and folate synthesis in susceptible bacteria. Sulfamethoxazole is most commonly formulated and used in combination with trimethoprim as co-trimoxazole to produce a synergistic bacteriostatic effect and broaden spectrum. Key technical attributes: high oral bioavailability, protein binding approximately 65 to 80 percent, hepatic metabolism primarily to N4-acetyl and glucuronide conjugates, renal and biliary excretion, and an elimination half-life in adults typically around 8 to 11 hours depending on renal function. Typical pharmaceutical forms include oral tablets, suspensions and fixed-dose combinations with trimethoprim. Quality control uses HPLC with UV detection for assay and related substances, with mass spectrometry used for impurity identification.
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole /Sulfadiazine/ Sulfadimethoxine
Parent: Sulfamethoxazole /Sulfadiazine / Sulfadimidine / Sulfadimethoxine
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Parent: Sulfamethoxazole
Related substances observed during synthesis, storage or metabolism include N4-acetylsulfamethoxazole, N-oxide species, desulfonated derivatives, and low-level aniline type process impurities, plus trace amounts of residual solvents and inorganic counterions depending on manufacture. Typical analytical acceptance criteria applied in batch release testing are reporting thresholds at or below 0.05 to 0.10 percent for unspecified impurities, individual identified impurities commonly limited to 0.2 to 0.5 percent depending on toxicological qualification, and total impurities typically controlled to not exceed about 1.0 percent. Control strategies include validated synthetic route controls, in-process purification, stability indicating HPLC methods for quantitation, and orthogonal identification by LC-MS, NMR or IR when required.
Sulfamethoxazole is used to treat a range of bacterial infections, commonly in combination with trimethoprim, including urinary tract infections, bronchitis, certain gastrointestinal infections and some forms of prostatitis. Its use is guided by organism susceptibility, site of infection and local treatment guidelines. A clinician selects therapy based on culture results, severity and patient factors.
Avoid prolonged sun exposure because sulfonamides can increase photosensitivity. Avoid concurrent use of medications that interact significantly, for example warfarin, methotrexate, phenytoin and certain oral hypoglycemics, without medical supervision. Avoid use in late pregnancy and in neonates unless clearly indicated. Maintain adequate hydration to reduce risk of crystalluria. Always inform your prescriber of existing liver or kidney disease and of other medicines you take.
No, sulfamethoxazole is a sulfonamide that interferes with folate synthesis, while amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. They belong to different classes, have different spectra of activity and different allergy and interaction profiles. Choice between them depends on the pathogen and clinical situation.
Clinical improvement is often seen within 48 to 72 hours for many uncomplicated infections when the pathogen is susceptible, but response time varies with infection severity, site and host factors. Laboratory markers and symptoms may lag, so complete the prescribed course unless advised otherwise by a healthcare professional.
